1. Generics Bulletin
  2. >>Business

Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m

Swedish Biosimilars Developer Retains Ranibizumab And Nivolumab Assets

 
• By Dave Wallace

Sweden’s Xbrane has struck a deal to transfer its R&D operations in Sweden and its Cimzia (certolizumab pegol) biosimilar candidate to Alvotech, in a transaction worth around $27m. However, Xbrane told Generics Bulletin that it was not getting out of biosimilar development altogether.

Xbrane’s R&D functions in Sweden will transfer to Alvotech (Shutterstock)

Alvotech has struck a deal worth SEK275m ($27.0m) to acquire Xbrane BioPharma’s R&D operations in Sweden – based in Campus Solna, at the Karolinska Institute outside Stockholm – as well as the firm’s XB003 proposed biosimilar to Cimzia (certolizumab pegol).

Xbrane will retain other pre-clinical assets – including its Ximluci (ranibizumab) rival to Lucentis and the Xdivane (nivolumab) planned biosimilar to Opdivo on which it is

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Products

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.